| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/19/2001 | WO2001027285A1 A novel polypeptide, a human dpb methyltransferase 41 and the polynucleotide encoding the polypeptide |
| 04/19/2001 | WO2001027283A1 A novel polypeptide, a human reverse transcriptase like protein 16 and the polynucleotide encoding the polypeptide |
| 04/19/2001 | WO2001027281A1 Designing immunogens |
| 04/19/2001 | WO2001027280A1 Antimicrobial compositions |
| 04/19/2001 | WO2001027277A2 Proteins and polynucleotides encoded thereby |
| 04/19/2001 | WO2001027276A2 Dna sequences from breast tumor and uses thereof |
| 04/19/2001 | WO2001027273A1 Human galanin family proteins and polynucleotides encoding the same |
| 04/19/2001 | WO2001027272A1 Oculomedin and glaucoma |
| 04/19/2001 | WO2001027271A1 Novel c-type lectin and gene thereof |
| 04/19/2001 | WO2001027270A1 Gene ys68 concerning early hematopoiesis |
| 04/19/2001 | WO2001027269A2 Vip54 protein and related materials |
| 04/19/2001 | WO2001027268A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 04/19/2001 | WO2001027267A2 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions |
| 04/19/2001 | WO2001027265A1 Nucleic acid sequences of hyperplasia and tumours of the thyroid |
| 04/19/2001 | WO2001027262A1 Gene selection using pnas |
| 04/19/2001 | WO2001027261A2 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 04/19/2001 | WO2001027257A1 Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof |
| 04/19/2001 | WO2001027249A1 Novel gene encoding a dna methyltransferase, dnmt3l |
| 04/19/2001 | WO2001027244A1 Body member with adjustable stiffness and frequency |
| 04/19/2001 | WO2001027243A1 Gene and methods for diagnosing neuropsychiatric disorders and treating such disorders |
| 04/19/2001 | WO2001027159A2 Polypeptides for detection and elimination of ca19-9 antigen positive cells |
| 04/19/2001 | WO2001027157A1 A biologically active complex of nr6 and cardiotrophin-like-cytokine |
| 04/19/2001 | WO2001027156A1 Interleukin-2 like protein and nucleic acids encoding same |
| 04/19/2001 | WO2001027154A2 Membrane translocating peptide drug delivery system |
| 04/19/2001 | WO2001027153A1 A murine seven-transmembrane receptor, mus musculus mhneaa81 |
| 04/19/2001 | WO2001027152A1 Method of altering polypeptide aggregation |
| 04/19/2001 | WO2001027151A1 A new polypeptide-human zinc finger protein kruppel family member zfp-52 and the polynucleotide encoding it |
| 04/19/2001 | WO2001027148A1 A novel polypeptide-homo glutamine(q)-rich factor 56 and polynucleotide encoding said polypeptide |
| 04/19/2001 | WO2001027147A1 A novel molecule |
| 04/19/2001 | WO2001027143A1 Lantibiotic |
| 04/19/2001 | WO2001027141A1 Inhibitors of factor xa having an arginine or arginine aldehyde mimic |
| 04/19/2001 | WO2001027140A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | WO2001027139A1 Drug for treatment of immunodeficiency states |
| 04/19/2001 | WO2001027138A2 Modulators of srebp processing |
| 04/19/2001 | WO2001027136A2 Peptides which stimulate the immune response and tissue regeneration |
| 04/19/2001 | WO2001027132A1 Estradiol conjugates and uses thereof |
| 04/19/2001 | WO2001027102A1 Substituted diazepanes |
| 04/19/2001 | WO2001027096A1 Aminomethyl-(hetero)aryl derivatives and their use as tryptase inhibitors |
| 04/19/2001 | WO2001027079A2 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 04/19/2001 | WO2001027077A2 Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors |
| 04/19/2001 | WO2001026736A2 Intraspinal compositions containing botulinum toxin for treating pain |
| 04/19/2001 | WO2001026694A1 Gene therapy for cardiomyopathy |
| 04/19/2001 | WO2001026688A1 Percutaneous absorption promoters for electroporation |
| 04/19/2001 | WO2001026683A2 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses |
| 04/19/2001 | WO2001026682A2 Modified plant viruses and methods of use thereof |
| 04/19/2001 | WO2001026679A2 T-cells and molecules involved in immune regulation |
| 04/19/2001 | WO2001026678A1 Short segments of dap-kinase |
| 04/19/2001 | WO2001026677A1 Interferon complex and medicinal use thereof |
| 04/19/2001 | WO2001026676A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 04/19/2001 | WO2001026675A1 FcηRIA |
| 04/19/2001 | WO2001026674A2 Method for treating otic disorders |
| 04/19/2001 | WO2001026673A1 Antibiotic-metal complex and methods |
| 04/19/2001 | WO2001026672A1 Induction of a strong immune response to a self-tumor associated antigen |
| 04/19/2001 | WO2001026671A1 Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors |
| 04/19/2001 | WO2001026662A1 Pharmaceutical product suitable for use immunosuppressive therapy |
| 04/19/2001 | WO2001026661A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
| 04/19/2001 | WO2001026646A1 NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
| 04/19/2001 | WO2001026643A1 Inhibition of tumorigenic properties of melanoma cells |
| 04/19/2001 | WO2001026635A2 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/19/2001 | WO2001026628A1 Cationic dosper virosomes |
| 04/19/2001 | WO2001026627A1 Liposome encapsulated silver salt compositions |
| 04/19/2001 | WO2001026605A2 Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor |
| 04/19/2001 | WO2001026575A1 Methods of diagnosing and treating urinary incontinence |
| 04/19/2001 | WO2001026467A1 Methods of enhancing chemotherapy |
| 04/19/2001 | WO2001019846A8 Transgenically produced fusion proteins |
| 04/19/2001 | WO2001014557B1 Pd-1, a receptor for b7-4, and uses therefor |
| 04/19/2001 | WO2001003741B1 Growth hormone formulations |
| 04/19/2001 | WO2001003670A8 Method for controlled production of ultrafine microparticles and nanoparticles |
| 04/19/2001 | WO2001002565A3 Secreted protein zacrp4 |
| 04/19/2001 | WO2000078986B1 Regulation system of expression using nuclear ppar receptors |
| 04/19/2001 | WO2000078329A3 The use of the protein uk 114 for inhibiting organ transplant rejection |
| 04/19/2001 | WO2000077031A3 Muc1 ligands |
| 04/19/2001 | WO2000076309A3 Non-human transgenic animals deficient in gas6 function and their use |
| 04/19/2001 | WO2000074707A3 Use of interleukin-11 to treat hemorrhagic shock |
| 04/19/2001 | WO2000071078A3 Composition designed for implementing an antitumoral or antiviral treatment in a mammal |
| 04/19/2001 | WO2000070665A3 Long lasting anti-angiogenic peptides |
| 04/19/2001 | WO2000070086A9 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 04/19/2001 | WO2000068380A3 Extracellular matrix and adhesion-associated proteins |
| 04/19/2001 | WO2000067762A3 Selenium-containing pro-drugs for cancer therapy |
| 04/19/2001 | WO2000066730A3 Laminin 2 and methods for its use |
| 04/19/2001 | WO2000063357A8 Methods and compositions for modulating ciliary neurotrophic factor activity |
| 04/19/2001 | WO2000061132A8 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 04/19/2001 | WO2000053753A3 Promotion or inhibition of angiogenesis and cardiovascularization |
| 04/19/2001 | WO2000052039A3 Lectomedin materials and methods |
| 04/19/2001 | WO2000029623A3 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 04/19/2001 | WO2000029589A9 Methioninase gene therapy for tumor treatment |
| 04/19/2001 | WO2000026245A3 Human membrane transport proteins |
| 04/19/2001 | WO2000012720A9 Elongase genes and uses thereof |
| 04/19/2001 | WO1999056785A3 Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction |
| 04/19/2001 | WO1999053022A3 Selection of lineage specific cells after differentiation of progenitor cells |
| 04/19/2001 | WO1999051188A3 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| 04/19/2001 | US20010000344 N-(2-(R)-amino-3-mercaptopropyl)-L-penicillaminyl-1,2,3,4 -tetrahydro-3(S)-isoquinoline carbonyl methionine methylester cyclic disulfide, for example; administering as antitumor agent or to treat restenosis |
| 04/19/2001 | DE19947668A1 Tumorspezifischer Vektor für die Gentherapie A tumor-specific vector for gene therapy |
| 04/19/2001 | DE10039844A1 New vector useful in the treatment of malignant disease and other hyperplasia |
| 04/19/2001 | DE10038883A1 Imaging using digital, flat field receiver with sensor cells activated by rows, triggers them in predefined delay sequence to produce data yielding image |
| 04/19/2001 | CA2722337A1 Process for producing ubiquinone-10 |
| 04/19/2001 | CA2718652A1 Process for producing ubiquinone-10 |
| 04/19/2001 | CA2399093A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | CA2389652A1 Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte(ctl) responses and protect the vaccinated host against intracellular pathogens and cancer |
| 04/19/2001 | CA2388991A1 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |